ASH Clinical Practice Guidelines on Amyloidosis
ASH Seeks Public Comment on Draft Recommendations for Diagnosis of Amyloidosis
ASH is now accepting public comments on draft recommendations for the diagnosis of amyloidosis. Comments will be accepted through July 10, 2024. We invite all interested healthcare professionals, stakeholder organizations, and individuals to provide comments on these draft recommendations. Comments received will be provided to the guideline panel for review prior to finalizing the guidelines.
Please submit all comments to [email protected].
In 2021, in response to long-standing member interest, ASH initiated an effort to develop evidence-based clinical practice guidelines for hematology that meet the highest standards of development, rigor and trustworthiness. Development of these guidelines, including systematic evidence review, will be supported by a methodology team. With their partnership, ASH will work to convene an initial panel of experts to review evidence and formulate recommendations addressing the initial diagnostic evaluation and workup for amyloidosis in general (both types, AL and ATTR). A second panel covering the treatment of Amyloidosis will follow.
Download ASH鈥檚 COI policy to learn more about management of conflicts of interest in the development of Clinical Practice Guidelines by the 天美传媒 Society of Hematology.
ASH continues its long-standing commitment to supporting scientists and clinicians from backgrounds underrepresented in medicine and embraces diverse voices across the patient and health care communities. Learn more about ASH鈥檚 commitment to diversity, equity and inclusion in health care.